Moderna/$MRNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Ticker
$MRNA
Sector
Primary listing
Employees
5,800
Headquarters
Website
Moderna Metrics
BasicAdvanced
$10B
-
-$7.53
1.83
-
Price and volume
Market cap
$10B
Beta
1.83
52-week high
$86.80
52-week low
$23.15
Average daily volume
8M
Financial strength
Current ratio
3.926
Quick ratio
3.555
Long term debt to equity
7.426
Total debt to equity
7.426
Interest coverage (TTM)
-233.79%
Profitability
EBITDA (TTM)
-3,065
Gross margin (TTM)
-71.44%
Net profit margin (TTM)
-94.31%
Operating margin (TTM)
-106.34%
Effective tax rate (TTM)
1.43%
Revenue per employee (TTM)
$530,000
Management effectiveness
Return on assets (TTM)
-14.78%
Return on equity (TTM)
-27.50%
Valuation
Price to revenue (TTM)
3.288
Price to book
1.09
Price to tangible book (TTM)
1.1
Price to free cash flow (TTM)
-2.892
Free cash flow yield (TTM)
-34.58%
Free cash flow per share (TTM)
-9.067
Growth
Revenue change (TTM)
-39.05%
Earnings per share change (TTM)
-50.99%
3-year revenue growth (CAGR)
-48.85%
3-year earnings per share growth (CAGR)
-38.82%
What the Analysts think about Moderna
Analyst ratings (Buy, Hold, Sell) for Moderna stock.
Moderna Financial Performance
Revenues and expenses
Moderna Earnings Performance
Company profitability
Moderna News
AllArticlesVideos
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
Accesswire·4 hours ago
Moderna to Present at Upcoming Conferences in September 2025
Accesswire·1 day ago
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
Benzinga·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Moderna stock?
Moderna (MRNA) has a market cap of $10B as of August 22, 2025.
What is the P/E ratio for Moderna stock?
The price to earnings (P/E) ratio for Moderna (MRNA) stock is 0 as of August 22, 2025.
Does Moderna stock pay dividends?
No, Moderna (MRNA) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next Moderna dividend payment date?
Moderna (MRNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Moderna?
Moderna (MRNA) has a beta rating of 1.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.